Cascade testing in Italian Hereditary Breast Ovarian Cancer families: a missed opportunity for cancer prevention?

AbstractHealthy carriers ofBRCA1/2 pathogenic variants (PVs) may benefit from risk-reducing measures of proven efficacy. The main approach to identify these individuals is cascade testing, and strategies to support this complex process are under investigation. In Italy, cascade testing has received little attention; therefore, we analyzed the uptake and characteristics ofBRCA1/2 cascade testing in families diagnosed with HBOC between 2017 and 2019 at two Italian genetics centers. All blood relatives aged 18 years or older at September 2022 and who could be involved in the first step of cascade testing (i.e., all the living relatives closest to the proband) were included. In addition to first-degree relatives, individuals who were second-, third- or fourth-degree relatives were included if the closest relative(s) was/were deceased. Overall, 213 families were included (103, Genoa; 110, Bologna). Most probands were women affected by breast and/or ovarian cancer (86.4%, Genoa; 84.5%, Bologna), and the branch segregating the PV was known/suspected in 62% of families (62.1%, Genoa; 60.9%, Bologna). Overall, the uptake of cascade testing was 22.8% (25.8%, Genoa; 19.9%, Bologna; OR  = 0.59: 95%CI 0.43–0.82). It was strongly associated with female gender (OR = 3.31, 95%CI 2.38–4.59), age ≤ 70 years (<  30 years OR = 3.48, 95%CI 1.85–6.56; 30–70 years OR = 3.08, 95%CI 2.01–4.71), first-degree relationship with the proband (OR = 16.61, 95%CI 10.5...
Source: Familial Cancer - Category: Cancer & Oncology Source Type: research